secwatch.observer — SEC 8-K summary
======================================

Issuer:     Design Therapeutics, Inc. (DSGN)
CIK:        0001807120
Form:       8-K
Filed at:   2021-08-09T23:59:59+00:00
Accession:  0001564590-21-042617
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Design Therapeutics Q2 net loss $7.6M; FA GeneTAC on track for H1 2022 clinical start
--------------------------------------------------------------------------------

- Net loss $7.6M; R&D expenses $5.0M, G&A $2.7M; cash & investments $402.8M.
- Lead FA GeneTAC program: IND-enabling data support initiation of Phase 1 trial in H1 2022.
- Appointed Elizabeth Gordon, Ph.D., as SVP Regulatory Affairs; board expanded with Behanna & Prasad.
- DM1 GeneTAC program preclinical data planned for H2 2021.
- Well-tolerated FA GeneTAC doses in rodents/NHPs achieved CNS, heart, muscle concentrations above therapeutic threshold.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1807120/000156459021042617/0001564590-21-042617-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1807120/000156459021042617/dsgn-8k_20210809.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-042617

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer